PLRX (Pliant Therapeutics, Inc.) Prakiraan pendapatan perusahaan

Pliant Therapeutics - logo grafis emiten PLRX

Pliant Therapeutics (PLRX) brings together leading scientists to combat fibrosis, which is driving investor interest. The organization's future sales revenue illustrates this reaction, while 0.00 records a new level mark. A stable cash reserve ensures development independence, although business success is critically dependent on Bexotegrast trials and patent protection in the absence of current revenues.

PLRX - Pendapatan mangsa ngarep perusahaan Pliant Therapeutics ing rentang 04.07.2022 - 16.11.2026

Rincian metrik keuangan lan pasar pliantrx.com (PLRX)

- indikator valuasi pasar bisnis:
Analisis fundamental perusahaan:Pliant Therapeutics Inc
Produk mawa merek Pliant Therapeutics

Investors utilize quantitative discounted cash flow models to filter blue-chip assets. This indicator measures expected revenue, establishing capital protection thresholds against fundamental drawdowns. For Pliant Therapeutics (PLRX), this metric reflects the commercial potential of its R&D pipeline for treating fibrosis. The company's projected sales volume allows for the correlation of clinical trial risks with market value. Analysis based on the company's projected sales volume helps determine exit points.

Analisis perusahaan pesaing

Volume dodolan mangsa ngarep perusahaan VRTX (Vertex)|ALNY (Alnylam Pharmaceuticals, Inc.) - Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan Insmed INSM|UTHR (United Therapeutics Corp.) - Pendapatan sing dikarepake perusahaan|BioMarin Pharmaceutical - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan BBIO (BridgeBio Pharma, Inc.)|BGM Group Corp (BGM) - Prakiraan pendapatan perusahaan|Cogent Biosciences Inc (COGT) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan Xeris Biopharma Inc|KROS: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan arcturusrx.com (ARCT)|Volume dodolan mangsa ngarep perusahaan Eton Pharmaceuticals ETON|Prakiraan volume dodolan KMDA (kamada.com)|Prakiraan volume dodolan Fulcrum Therapeutics, Inc. FULC|Abeona Therapeutics - Prakiraan volume dodolan|mereobiopharma.com (MREO) - Volume dodolan mangsa ngarep perusahaan|Protalix BioTherapeutics Inc. (PLX) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan APLT (appliedtherapeutics.com)|RNTX (Rein Therapeutics Inc.) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan GELS|Volume dodolan mangsa ngarep perusahaan AYTU (aytubio.com)|Volume dodolan mangsa ngarep perusahaan Chemomab Therapeutics Ltd CMMB|Prakiraan volume dodolan SRXH (SRx Health Solutions Inc.)|Pendapatan mangsa ngarep perusahaan PLRZ|AEZS - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan CYTH (CTD Holdings)|INZY: Prakiraan volume dodolan|Pendapatan sing dikarepake perusahaan RPHM (Reneo Pharma)|Prakiraan pendapatan perusahaan cosciensbio.com